Physician profile
Alan W Cooper
NPI 1114096641
$2,176.82
in general payments reported to CMS, 2019-2025
24 companies · $397 in 2025
The $397 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $231 · 2021: $225 · 2022: $241 · 2023: $190 · 2024: $583 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $511.54 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Glaxosmithkline, LLC. | $222.78 | 2019-2025 | Bexsero, Pediarix |
| Sanofi-Aventis U.S. LLC | $222.14 | 2023-2025 | |
| Corium, LLC | $161.11 | 2022-2024 | Azstarys |
| Pfizer INC. | $133.14 | 2019-2025 | |
| Kaleo, INC. | $132.85 | 2019-2023 | Auvi-Q |
| Cranial Technologies, INC | $126.23 | 2020-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $126.00 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $111.38 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaqta |
| Supernus Pharmaceuticals, INC. | $78.89 | 2021-2025 | Qelbree |
| Alk-Abello, INC | $65.50 | 2025 | Neffy |
| Sobi, INC | $43.29 | 2019-2021 | |
| Seqirus USA INC | $37.27 | 2024 | Flucelvax |
| Acadia Pharmaceuticals INC | $35.86 | 2023-2024 | Daybue |
| Collegium Pharmaceutical, INC. | $35.56 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $18.86 | 2025 | Voxzogo 1.2mg |
| Aytu Biopharma, INC. | $17.96 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.13 | 2019 | |
| Genentech USA, INC. | $14.90 | 2019 | |
| Sanofi Pasteur INC. | $14.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 | |
| Hospira, INC. | $12.95 | 2022 | |
| Biogen, INC. | $12.68 | 2021 | |
| Neos Therapeutics, LP | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.